APOTEX CORP. for APOTEX CORP.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Manufacturing MAN
S. 2510, the RAPID Reserve Act, provisions relating to awarding contracts to US or OECD based generic drug manufacturers to establish a reserve of essential medicines; and Federal policy relating to addressing drug shortages and strengthening domestic pharmaceutical manufacturing capabilities.
Foreign entity interest: Artemis Parent, Inc., Artemis Intermediate Holdings, Inc., and Apotex Holdco Inc., the parent companies of Apotex Corp., and Apotex Inc., its affiliate, identified by the registrants first quarter 2024 LD-2 report, have direct or indirect interests in companies that manufacture and or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| ARTEMIS INTERMEDIATE HOLDINGS, INC. (ONTARIO REGISTERED)(AIHI) | Canada | Canada | 100.0% | — |
| ARTEMIS PARENT, INC. | Canada | Canada | 100.0% | — |
| APOTEX HOLDCO INC. (ONTARIO REGISTERED)(HOLDCO) | Canada | Canada | 100.0% | — |
| APOTEX INC. | Canada | Canada | — | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.